Hemophilia B Latest Advances

Orthopedic treatment strategy for hemophilic pseudotumor

Journal: Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery

Published: June 21, 2026

Discovery and optimization of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia A and B.

Journal: mAbs

Published: June 11, 2026

Six-year FIX-padua gene therapy in hemophilia B.

Journal: Blood advances

Published: May 15, 2026

Bleeding Frequency and Its Association With Joint Health and Functional Independence in Hemophilia: A Cross-Sectional Study Using the Hemophilia Joint Health Score (HJHS) and Functional Independence Score in Hemophilia (FISH).

Journal: Cureus

Published: April 16, 2026

Haemorrhagic Cholecystitis: A Rare Form of Haemorrhagic Shock in a Patient With a Double Risk.

Journal: Cureus

Published: April 13, 2026

Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B.

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Published: April 06, 2026

Clinical Scenarios in Hospitalized Patients With Hemophilia.

Journal: Cureus

Published: March 30, 2026

Optimizing Perioperative Management of Haemophilia B With rFIX-FP: Pharmacokinetic Validation of the Hemoptidose Tool.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: March 26, 2026

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

Journal: The Cochrane database of systematic reviews

Published: March 24, 2026

Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec.

Journal: CPT: pharmacometrics & systems pharmacology

Published: March 19, 2026

Effect of marstacimab in young people living with severe hemophilia A or moderate to severe hemophilia B without inhibitors: A plain language summary from the BASIS study.

Journal: Therapeutic advances in hematology

Published: March 17, 2026

A plain language summary of the BASIS study looking at people living with severe hemophilia A or B with inhibitors and being treated with marstacimab.

Journal: Therapeutic advances in hematology

Published: March 11, 2026

Hemophilia B Latest Advances

Find the Latest Research About Hemophilia B

Orthopedic treatment strategy for hemophilic pseudotumor

Orthopedic treatment strategy for hemophilic pseudotumor

Discovery and optimization of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia A and B.

Discovery and optimization of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia A and B.

Six-year FIX-padua gene therapy in hemophilia B.

Six-year FIX-padua gene therapy in hemophilia B.

Bleeding Frequency and Its Association With Joint Health and Functional Independence in Hemophilia: A Cross-Sectional Study Using the Hemophilia Joint Health Score (HJHS) and Functional Independence Score in Hemophilia (FISH).

Bleeding Frequency and Its Association With Joint Health and Functional Independence in Hemophilia: A Cross-Sectional Study Using the Hemophilia Joint Health Score (HJHS) and Functional Independence Score in Hemophilia (FISH).

Haemorrhagic Cholecystitis: A Rare Form of Haemorrhagic Shock in a Patient With a Double Risk.

Haemorrhagic Cholecystitis: A Rare Form of Haemorrhagic Shock in a Patient With a Double Risk.

Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B.

Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B.

Clinical Scenarios in Hospitalized Patients With Hemophilia.

Clinical Scenarios in Hospitalized Patients With Hemophilia.

Optimizing Perioperative Management of Haemophilia B With rFIX-FP: Pharmacokinetic Validation of the Hemoptidose Tool.

Optimizing Perioperative Management of Haemophilia B With rFIX-FP: Pharmacokinetic Validation of the Hemoptidose Tool.

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec.

Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec.

Effect of marstacimab in young people living with severe hemophilia A or moderate to severe hemophilia B without inhibitors: A plain language summary from the BASIS study.

Effect of marstacimab in young people living with severe hemophilia A or moderate to severe hemophilia B without inhibitors: A plain language summary from the BASIS study.

A plain language summary of the BASIS study looking at people living with severe hemophilia A or B with inhibitors and being treated with marstacimab.

A plain language summary of the BASIS study looking at people living with severe hemophilia A or B with inhibitors and being treated with marstacimab.